BIO InvestorForum 2007
Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, today announced that the Company’s Chairman and CEO, Richard B. Hollis, is currently scheduled to present at the following investor conferences and forums: